KIRKLAND, QC, Nov. 24, 2015 /CNW Telbec/ – Ortho Regenerative Technologies Inc. (“Ortho RTi”), a Canadian orthopaedic biotechnology company, announced today that it has filed a preliminary prospectus with the securities regulatory authorities of all provinces and territories in Canada.
The non-financing prospectus was filed in connection with a proposed distribution by Manitex Capital Inc. (“Manitex”) of a maximum of 1,256,127 Class “A” common shares of Ortho RTi to holders of Manitex common shares as a dividend-in-kind. The dividend would be paid on the basis of one Class “A” common share of Ortho RTi for every ten Manitex common shares which are outstanding on the record date to be fixed by the board of directors of Manitex.
Prior to the filing of the final prospectus, Ortho RTi will apply to list its Class “A” common shares on a Canadian stock exchange. Listing will be subject to Ortho RTi fulfilling all of the listing requirements of that stock exchange. 
The preliminary prospectus can be found on SEDAR at www.sedar.com.
About Ortho RTi
Ortho Regenerative Technologies Inc is a Canadian orthopaedic biotechnology company dedicated to the development of medical devices to treat unmet needs in the orthopaedic market. Based on a proprietary biopolymer platform, the company is developing new regenerative treatments for soft tissue tears in the shoulder and knee as well as articular cartilage injuries, all currently with few productive options for repair.